VulnerabilityModified
CVE-2019-15931
Intesync Solismed 3.3sp allows Directory Traversal, a different vulnerability than CVE-2019-16246.
CRITICAL 9.8EPSS 2.73%
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (2.73%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
Intesync Solismed 3.3sp allows Directory Traversal, a different vulnerability than CVE-2019-16246.
- CVSS 3.1
- 9.8 CRITICALCVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
- EPSS
- 2.73% probability · 85th percentile
- CISA KEV
- Not listed
- Weakness
- CWE-22
- Affected
- intesync/solismed
- Source
- cve@mitre.org
References
- https://bishopfox.comThird Party Advisory
- https://know.bishopfox.com/advisories/solismed-criticalExploit, Third Party Advisory
- https://www.bishopfox.com/blog/news-category/advisories/Third Party Advisory
- https://www.solismed.com/Product
- https://bishopfox.comThird Party Advisory
- https://know.bishopfox.com/advisories/solismed-criticalExploit, Third Party Advisory
- https://www.bishopfox.com/blog/news-category/advisories/Third Party Advisory
- https://www.solismed.com/Product
Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.